{"id":578,"date":"2025-03-24T11:44:00","date_gmt":"2025-03-24T11:44:00","guid":{"rendered":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/?page_id=578"},"modified":"2025-03-24T11:55:27","modified_gmt":"2025-03-24T11:55:27","slug":"chief-pd-2","status":"publish","type":"page","link":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/chief-pd-2\/","title":{"rendered":"CHIEF-PD"},"content":{"rendered":"\n
\n
\"\"<\/figure>\n\n\n\n

Parkinson’s Disease Research<\/h3>\n\n\n\n

The CHIEF-PD trial is a phase 3 randomized, double-blind, placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s disease. The trial aims to determine whether treatment with cholinesterase inhibitors (ChEi) reduces the rate of falls in Parkinson’s disease. The primary objective of the trial is to determine the difference in fall rate over 12 months between people with Parkinson’s disease treated with a ChEi and those treated with a placebo. Secondary objectives include assessing the effect of treatment on Parkinson’s disease severity, freezing of gait, frailty and physical performance, cognition, depression, apathy, fear of falling, dysphagia, participant\/caregiver quality of life, and healthcare costs. The primary outcome measure is fall rate measured using monthly diaries and telephone calls over 12 months from the start of the intervention. The NDN in Edinburgh is one of the sites in this multicenter study and with positive findings will be providing robust evidence to change clinical practice.<\/p>\n<\/div><\/div>\n\n\n